Welcome to our dedicated page for Tactile Systems news (Ticker: TCMD), a resource for investors and traders seeking the latest updates and insights on Tactile Systems stock.
Tactile Systems Technology, Inc. reports news as a medical technology company that develops and markets at-home therapies for chronic disorders. Its updates center on lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease, including products and platforms such as Flexitouch Plus, AffloVest airway clearance devices and LymphaTech's digital 3D measurement and monitoring technology.
Recurring company developments include quarterly financial results, clinical evidence for home-based therapies, FDA device clearances, product portfolio expansion, order-management and reimbursement workflow initiatives, acquisitions, share repurchase activity and board governance changes. The company's news also describes its work with clinicians to expand awareness and access to care for patients using at-home therapy systems.
Tactile Medical (Nasdaq: TCMD) announced that management will present at the William Blair 46th Annual Growth Stock Conference at the Loews Hotel in Chicago from June 2-4, 2026. The company’s presentation is scheduled for Tuesday, June 2, at 9:20 a.m. CT.
A live audio webcast and replay will be available in the “Events & Webcasts” section of Tactile Medical’s investor relations website. Tactile Medical develops at-home therapies for chronic conditions such as lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease.
Tactile Systems Technology (Nasdaq: TCMD) reported Q1 2026 results: revenue $75.3M (+23% YoY), gross margin 76.5%, net loss $1.8M (‑$0.08/share), and Adjusted EBITDA $3.7M. The company repurchased $1.1M of stock, closed the LymphaTech acquisition, received FDA 510(k) clearance for a next‑gen AffloVest device, and updated 2026 revenue guidance to $360M–$368M.
Balance sheet: cash $75.0M, no borrowings; $23.9M remains available under the $25M repurchase program.
Tactile Medical (Nasdaq: TCMD) will release first quarter fiscal 2026 results after market close on May 4, 2026. Management will host a conference call and webcast at 5:00 p.m. ET the same day; a replay will be available for two weeks and the webcast will be archived on the investor site.
Tactile Medical (Nasdaq: TCMD) appointed Andrea Pearson to its Board of Directors effective March 9, 2026, and named her to the Compliance & Reimbursement and Nominating & Corporate Governance Committees. Ms. Pearson brings 25+ years of healthcare growth, product and marketing experience.
Her background includes senior roles at DispatchHealth and HealthGrades, where she led large-scale market expansion and audience growth, and most recently served as Growth Advisor and CMO at Harbor Health. The appointment supports Tactile Medical's focus on expanding access and clinical engagement for at-home therapies.
Tactile Medical (Nasdaq: TCMD) reported Q4 2025 revenue of $103.6M (+21% YoY) and full-year 2025 revenue of $329.5M (+12% YoY). Gross margin expanded to 78% in Q4 and 76% for the year. Adjusted EBITDA rose to $22.9M in Q4 and $44.8M for 2025.
Key balance-sheet moves: repaid $26.3M term loan, repurchased $26.5M of stock, and ended 2025 with $83.4M cash. 2026 guidance: revenue $357M–$365M and adjusted EBITDA $49M–$51M.
Tactile Medical (Nasdaq: TCMD) acquired LymphaTech on February 17, 2026 for an upfront cash payment of $6.8 million, plus potential milestone-based additional consideration. The deal adds LymphaTech’s clinically validated 3D full-body measurement platform to Tactile’s lymphedema portfolio and brings founders into Tactile to drive commercialization and research.
The acquisition aims to improve disease identification, enable longitudinal monitoring, support compression garment digitization, and strengthen R&D for next‑generation lymphatic therapies.
Tactile Medical (Nasdaq: TCMD) will release fourth quarter and fiscal year 2025 financial results after the market closes on February 17, 2026. Management will host a conference call and Q&A at 5:00 p.m. ET the same day.
Dial-in details: 877-407-3088 (international 201-389-0927), access code 13758303. A live webcast and archived replay will be available at investors.tactilemedical.com and a phone replay for two weeks.
About Tactile Medical: the company develops at-home therapies for chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease.
Tactile Medical (Nasdaq: TCMD) said management will participate in the Piper Sandler 37th Annual Healthcare Conference at the Lotte New York Palace in New York, NY from December 2–4, 2025.
The company will take part in a fireside chat on December 2, 2025 at 8:00 a.m. Central Time. A live audio webcast will be available in the Events & Webcasts section of the company investor relations site (http://investors.tactilemedical.com), and an archive will be posted for replay after the conference.
Tactile Medical (Nasdaq: TCMD) reported Q3 2025 results on November 3, 2025, with total revenue $85.8M (+17% YoY), gross margin 76%, net income $8.2M ($0.36 diluted) and Adjusted EBITDA $14.4M. The company repaid its $24.0M term loan, refinanced its revolver to $40M capacity, and authorized a $25M share repurchase program (expires Nov 3, 2027). Full‑year 2025 guidance was raised to $317M–$321M revenue and $38M–$39.5M adjusted EBITDA. Cash was $66.0M at Sept 30, 2025.
Tactile Medical (Nasdaq: TCMD) presented six-month results from a large randomized controlled trial showing sustained clinical benefits of Flexitouch Plus as first-line therapy for head and neck cancer–related lymphedema.
Key findings: sustained symptom improvement in both study arms, objective swelling reductions at 13 of 19 internal sites with statistically significant decreases at the base of tongue (p=0.008) and arytenoids (p=0.023), and clinician-reported measures favoring Flexitouch Plus. The trial enrolled 236 patients across 10 centers and confirms durability of benefit through six months following earlier two-month data.